Grŵp Strategaeth Meddyginiaethau Cymru Gyfan
All Wales Medicines Strategy Group

Final Appraisal Recommendation

Advice No: 1617 – September 2017

Desmopressin acetate (Noqdirna®) 25 microgram and 50 microgram oral lyophilisate

Submission by Ferring Pharmaceuticals

Recommendation of AWMSG

Desmopressin acetate (Noqdirna®) for the treatment of nocturia due to idiopathic nocturnal polyuria in adults is recommended for restricted use within NHS Wales.

Desmopressin acetate (Noqdirna®) should be restricted for use in the following subpopulation within its licensed indication for the treatment of nocturia due to idiopathic nocturnal polyuria in adults:

- **aged over 65, for whom treatment options are currently limited.**

Desmopressin acetate (Noqdirna®) is not recommended for use within NHS Wales outside of this subpopulation.

Additional note(s):

- Cost-effectiveness evidence was only provided for a subpopulation of patients aged over 65.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3282), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Ferring Pharmaceuticals
Date of first issue	September 2017
Last reviewed	October 2020